1h Free Analyst Time
The publisher has been monitoring the breast cancer liquid biopsy testing devices market and it is poised to grow by $ 730.4 mn during 2022-2026, accelerating at a CAGR of 23.58% during the forecast period. Our report on the breast cancer liquid biopsy testing devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of breast cancer, increasing preference for non-invasive procedures, and rising number of new product launches and FDA approvals.
The breast cancer liquid biopsy testing devices market analysis includes the type segment and geographic landscape.
The publisher's breast cancer liquid biopsy testing devices market is segmented as below:
By Type
- CTCs and circulating nucleic acids
- Extracellular vesicles
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the technological advances as one of the prime reasons driving the breast cancer liquid biopsy testing devices market growth during the next few years. Also, growing emphasis on breast cancer diagnosis and increasing focus on direct-to-customer marketing will lead to sizable demand in the market.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on breast cancer liquid biopsy testing devices market covers the following areas:
- Breast cancer liquid biopsy testing devices market sizing
- Breast cancer liquid biopsy testing devices market forecast
- Breast cancer liquid biopsy testing devices market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading breast cancer liquid biopsy testing devices market vendors that include A. Menarini Industrie Farmaceutiche Riunite Srl, Agena Bioscience Inc., Bio Rad Laboratories Inc., Exact Sciences Corp., F. Hoffmann La Roche Ltd., Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Isogen Life Science BV, Myriad Genetics Inc., Natera Inc., NeoGenomics Laboratories Inc., Novogene Corp., OncoDNA SA, Pfizer Inc., QIAGEN NV, SAGA Diagnostics AB, Sysmex Corp., and Thermo Fisher Scientific Inc. Also, the breast cancer liquid biopsy testing devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.
The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Exhibits:
Executive Summary
The publisher recognizes the following companies as the key players in the global breast cancer liquid biopsy testing devices market: A. Menarini Industrie Farmaceutiche Riunite Srl, Agena Bioscience Inc., Bio Rad Laboratories Inc., Exact Sciences Corp., F. Hoffmann La Roche Ltd., Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Isogen Life Science BV, Myriad Genetics Inc., Natera Inc., NeoGenomics Laboratories Inc., Novogene Corp., OncoDNA SA, Pfizer Inc., QIAGEN NV, SAGA Diagnostics AB, Sysmex Corp., and Thermo Fisher Scientific Inc.Commenting on the report, an analyst from the publisher said: "The latest trend gaining momentum in the market is technological advances."
According to the report, one of the major drivers for this market is the increasing prevalence of breast cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Agena Bioscience Inc.
- Bio Rad Laboratories Inc.
- Exact Sciences Corp.
- F. Hoffmann La Roche Ltd.
- Fluxion Biosciences Inc.
- Guardant Health Inc.
- Illumina Inc.
- Isogen Life Science Bv
- Myriad Genetics Inc.
- Natera Inc.
- Neogenomics Laboratories Inc.
- Novogene Corp.
- Oncodna Sa
- Pfizer Inc.
- Qiagen Nv
- Saga Diagnostics Ab
- Sysmex Corp.
- Thermo Fisher Scientific Inc.
